TCRX — Tscan Therapeutics Balance Sheet
0.000.00%
- $56.25m
- -$63.62m
- $10.33m
Annual balance sheet for Tscan Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 161 | 120 | 192 | 290 | 152 |
| Prepaid Expenses | |||||
| Total Current Assets | 166 | 124 | 194 | 293 | 157 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 17.3 | 69.2 | 71.2 | 71.6 | 66.4 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 188 | 199 | 272 | 371 | 229 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 21.3 | 17.3 | 29.8 | 36 | 18.7 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 27.3 | 99.7 | 121 | 130 | 106 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 161 | 99.4 | 151 | 241 | 123 |
| Total Liabilities & Shareholders' Equity | 188 | 199 | 272 | 371 | 229 |
| Total Common Shares Outstanding |